Compare CRTO & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRTO | FTRE |
|---|---|---|
| Founded | 2005 | 1996 |
| Country | France | United States |
| Employees | 3649 | N/A |
| Industry | Advertising | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 780.6M | 829.3M |
| IPO Year | 2013 | 2023 |
| Metric | CRTO | FTRE |
|---|---|---|
| Price | $16.41 | $15.48 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 9 |
| Target Price | ★ $34.00 | $14.06 |
| AVG Volume (30 Days) | 235.3K | ★ 1.4M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.95 | N/A |
| EPS | ★ 0.15 | N/A |
| Revenue | $2,296,692,000.00 | ★ $2,723,400,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.54 | $3.09 |
| P/E Ratio | $5.92 | ★ N/A |
| Revenue Growth | ★ 27.65 | 1.00 |
| 52 Week Low | $15.58 | $3.97 |
| 52 Week High | $28.91 | $18.67 |
| Indicator | CRTO | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 37.25 | 81.17 |
| Support Level | N/A | $8.85 |
| Resistance Level | $20.10 | $18.26 |
| Average True Range (ATR) | 0.90 | 0.85 |
| MACD | -0.31 | 0.61 |
| Stochastic Oscillator | 18.63 | 90.00 |
Criteo SA is an ad-tech company in the digital advertising market. Its technology allows retailer advertisers to launch multichannel and cross-device marketing campaigns in real time. With real-time return on investment analysis of the ads, the firm's clients can adjust their marketing strategies dynamically. It has two reportable segments: Retail Media and Performance Media. Retail Media: This segment encompasses revenue generated from brands, agencies, and retailers for the purchase and sale of retail media digital advertising inventory and audiences, and services. Performance Media: This segment encompasses targeting capabilities and supply and AdTech services. The majority of its revenues is generated from the performance media segment.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.